[1]
Jacobson TA, Maki KC, Orringer CE, Jones PH, Kris-Etherton P, Sikand G, La Forge R, Daniels SR, Wilson DP, Morris PB, Wild RA, Grundy SM, Daviglus M, Ferdinand KC, Vijayaraghavan K, Deedwania PC, Aberg JA, Liao KP, McKenney JM, Ross JL, Braun LT, Ito MK, Bays HE, Brown WV, Underberg JA, NLA Expert Panel. National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia: Part 2. Journal of clinical lipidology. 2015 Nov-Dec:9(6 Suppl):S1-122.e1. doi: 10.1016/j.jacl.2015.09.002. Epub 2015 Sep 18
[PubMed PMID: 26699442]
[2]
Jacobson TA, Ito MK, Maki KC, Orringer CE, Bays HE, Jones PH, McKenney JM, Grundy SM, Gill EA, Wild RA, Wilson DP, Brown WV. National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1 - executive summary. Journal of clinical lipidology. 2014 Sep-Oct:8(5):473-88. doi: 10.1016/j.jacl.2014.07.007. Epub 2014 Jul 15
[PubMed PMID: 25234560]
[3]
Jellinger PS. Impact of new lipid management guidelines on the treatment of extreme and very high-risk patients: AACE/ACE and AHA/ACC guidelines. Journal of diabetes. 2020 Feb:12(2):105-109. doi: 10.1111/1753-0407.12998. Epub 2019 Nov 27
[PubMed PMID: 31777166]
[4]
Jellinger PS, Handelsman Y, Rosenblit PD, Bloomgarden ZT, Fonseca VA, Garber AJ, Grunberger G, Guerin CK, Bell DSH, Mechanick JI, Pessah-Pollack R, Wyne K, Smith D, Brinton EA, Fazio S, Davidson M, Zangeneh F, Bush MA. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE - EXECUTIVE SUMMARY(Complete Appendix to Guidelines available at http://journals.aace.com). Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. 2017 Apr 2:23(4):479-497. doi: 10.4158/EP171764.GL. Epub 2017 Feb 3
[PubMed PMID: 28156151]
[5]
Lloyd-Jones DM, Morris PB, Ballantyne CM, Birtcher KK, Daly DD Jr, DePalma SM, Minissian MB, Orringer CE, Smith SC Jr. 2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. Journal of the American College of Cardiology. 2017 Oct 3:70(14):1785-1822. doi: 10.1016/j.jacc.2017.07.745. Epub 2017 Sep 5
[PubMed PMID: 28886926]
Level 3 (low-level) evidence
[6]
Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE, Goldberg R, Heidenreich PA, Hlatky MA, Jones DW, Lloyd-Jones D, Lopez-Pajares N, Ndumele CE, Orringer CE, Peralta CA, Saseen JJ, Smith SC Jr, Sperling L, Virani SS, Yeboah J. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Journal of the American College of Cardiology. 2019 Jun 25:73(24):e285-e350. doi: 10.1016/j.jacc.2018.11.003. Epub 2018 Nov 10
[PubMed PMID: 30423393]
Level 1 (high-level) evidence
[7]
Samaha FF, McKenney J, Bloedon LT, Sasiela WJ, Rader DJ. Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemia. Nature clinical practice. Cardiovascular medicine. 2008 Aug:5(8):497-505. doi: 10.1038/ncpcardio1250. Epub 2008 May 27
[PubMed PMID: 18506154]
[8]
Andrus B, Lacaille D. 2013 ACC/AHA guideline on the assessment of cardiovascular risk. Journal of the American College of Cardiology. 2014 Jul 1:63(25 Pt A):2886. doi: 10.1016/j.jacc.2014.02.606. Epub 2014 Apr 23
[PubMed PMID: 24768878]
[9]
Ajufo E, Rader DJ. New Therapeutic Approaches for Familial Hypercholesterolemia. Annual review of medicine. 2018 Jan 29:69():113-131. doi: 10.1146/annurev-med-051215-030943. Epub
[PubMed PMID: 29414257]
[10]
Khoury E, Brisson D, Roy N, Tremblay G, Gaudet D. Review of the long-term safety of lomitapide: a microsomal triglycerides transfer protein inhibitor for treating homozygous familial hypercholesterolemia. Expert opinion on drug safety. 2019 May:18(5):403-414. doi: 10.1080/14740338.2019.1602606. Epub 2019 May 16
[PubMed PMID: 30945578]
Level 3 (low-level) evidence
[11]
Crismaru I, Pantea Stoian A, Bratu OG, Gaman MA, Stanescu AMA, Bacalbasa N, Diaconu CC. Low-density lipoprotein cholesterol lowering treatment: the current approach. Lipids in health and disease. 2020 May 6:19(1):85. doi: 10.1186/s12944-020-01275-x. Epub 2020 May 6
[PubMed PMID: 32375792]
[12]
. Lipid-lowering drugs. The Medical letter on drugs and therapeutics. 2019 Feb 11:61(1565):17-24
[PubMed PMID: 30845106]
Level 3 (low-level) evidence
[13]
Cuchel M, Bloedon LT, Szapary PO, Kolansky DM, Wolfe ML, Sarkis A, Millar JS, Ikewaki K, Siegelman ES, Gregg RE, Rader DJ. Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. The New England journal of medicine. 2007 Jan 11:356(2):148-56
[PubMed PMID: 17215532]
[14]
Cuchel M, Meagher EA, du Toit Theron H, Blom DJ, Marais AD, Hegele RA, Averna MR, Sirtori CR, Shah PK, Gaudet D, Stefanutti C, Vigna GB, Du Plessis AM, Propert KJ, Sasiela WJ, Bloedon LT, Rader DJ, Phase 3 HoFH Lomitapide Study investigators. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet (London, England). 2013 Jan 5:381(9860):40-6. doi: 10.1016/S0140-6736(12)61731-0. Epub 2012 Nov 2
[PubMed PMID: 23122768]
[15]
Cupido AJ, Reeskamp LF, Kastelein JJP. Novel lipid modifying drugs to lower LDL cholesterol. Current opinion in lipidology. 2017 Aug:28(4):367-373. doi: 10.1097/MOL.0000000000000428. Epub
[PubMed PMID: 28445176]
Level 3 (low-level) evidence
[16]
Dixon DL, Sisson EM, Butler M, Higbea A, Muoio B, Turner B. Lomitapide and mipomersen: novel lipid-lowering agents for the management of familial hypercholesterolemia. The Journal of cardiovascular nursing. 2014 Sep-Oct:29(5):E7-E12. doi: 10.1097/JCN.0000000000000104. Epub
[PubMed PMID: 24231894]
[17]
Jacobson TA, Ito MK, Maki KC, Orringer CE, Bays HE, Jones PH, McKenney JM, Grundy SM, Gill EA, Wild RA, Wilson DP, Brown WV. National lipid association recommendations for patient-centered management of dyslipidemia: part 1--full report. Journal of clinical lipidology. 2015 Mar-Apr:9(2):129-69. doi: 10.1016/j.jacl.2015.02.003. Epub 2015 Apr 7
[PubMed PMID: 25911072]